Research and Markets (http://www.researchandmarkets.com/research/3kb6kb/_the_human) has announced the addition of the " The Human Microbiome: Biomedical Implications and Birth of a Market - Overview" report to their offering.
This report covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease.
Results from the Human Microbiome Project and other massive studies of human bacterial symbionts, which far outnumber human cells in the body, have drawn lots of attention in recent years from both the basic and applied biomedical research communities. During 2009, a PubMed search on the term human microbiome' yielded 579 citations, but for 2013 that number had increased to 3,324.
A number of new commercial ventures have sprung up in recent years to develop therapies and biomarkers for a number of common chronic conditions, notably inflammatory, metabolic, and autoimmune diseases. Most such programs are based on the notion that disruption of relatively stable microbiome ecosystems results in dysbioses, i.e., imbalances that in turn destabilize homeostasis and create the conditions for diseases to arise and flourish.
This report focuses on biomedical aspects of human microbiome research, development, and commerce. It covers necessary background material, evolution of the field, progress in basic research, activities in the developing commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Information for the report has been drawn from the scientific literature, discussions with knowledgeable individuals, and an online survey of people working in this area.
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Background and Evolution of Human Microbiome R&D
Chapter 3: Research on the Human Microbiome
Chapter 4: Commercial Aspects of Microbiome Research and Development
Chapter 5: Market Survey
Chapter 6: Trends and Conclusions
Chapter 7: Interview Transcripts
Companies Mentioned
- 4D Pharma
- ActoGenixAOBiome
- AvidBiotics
- CIPAC Limited
- Enterome Bioscience
- Human Longevity
- Metabiomics
- Microbiome Therapeutics
- Miomics
- OmniBiome Therapeutics
- OptiBiotix
- Osel Inc
- OxThera
- PathoGenetix
- Rebiotix
- Ritter Pharmaceuticals
- Second Genome
- Seres Health
- uBiome
- UCB
- UC San Francisco
- Vedanta
- ViThera Pharmaceuticals
- Whole Biome
For more information visit http://www.researchandmarkets.com/research/3kb6kb/_the_human
